UNSPSC 51292901: Cianopramine

This classification denotes a serotonin antagonist with the molecular formula C20H23N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 02MNR4P2PM, chemically known as 5h-dibenz(b,f)azepine-3-carbonitrile, 5-(3-(dimethylamino)propyl)-10,11-dihydro- but generally known as cianopramine, which bears US NIH Compound Identifier 48126. European Medicines Agency schedules Cianopramine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06227MIG. The term CIANOPRAMINE is an International Non-Proprietary Name.

UNSPSC 51292901 Cianopramine, a Commodity code, represents pharmaceutical products that state and local governments procure for community health, pharmacy benefit, and emergency response programs. The recent activity shows no direct procurement of cianopramine itself; instead, opportunities tagged to this code reflect broader pharmaceutical supply arrangements including naloxone, generic multi-source drugs, and over-the-counter products distributed through authorized wholesale channels to state health departments, county health systems, and cooperative purchasing alliances serving multiple jurisdictions.

Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota MMCAP, which serves state and local government facilities across multiple states including Oregon). Representative recent opportunities include Seminole County's IFB60459723LAS, an invitation for bid posted June 30, 2026, for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023; Texas HHS Commission's RFI HHS0017013, posted April 3, 2026, seeking vendor capabilities for a direct-to-manufacturer prescription program; and Minnesota MMCAP's S1070000015802, a request for proposal issued January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a proposal deadline of March 26, 2026. Activity concentrates in Florida, Texas, and Minnesota, with MMCAP's multistate structure extending reach across participating jurisdictions. The code shows limited direct pharmaceutical-manufacturer activity; most procurement flows through authorized wholesale distributors or cooperative frameworks with compliance requirements including cGMP certification, Drug Supply Chain Security Act adherence, and substantial insurance coverage mandates.